1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,723 | 0,745 | 28.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 1.772 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 790 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.154 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Nanoform senkt Cashburn im dritten Quartal, Aktie gibt dennoch nach | 12 | Investing.com Deutsch | ||
| 12.11.25 | Nanoform Finland Oyj Q3 Sales Decline | 8 | RTTNews | ||
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.565 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 500 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 720 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 773 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 751 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08.25 | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.619 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen | |
| 12.06.25 | Nanoform Finland Oyj: Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide | 1.113 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | June 12, 2025 at 08:10:00 EEST
HELSINKI, FINLAND, June 12, 2025 - Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had... ► Artikel lesen | |
| 20.05.25 | Nanoform Finland Oyj: Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS technology | 1.451 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 20, 2025 at 08:10:00 EEST
Term sheets agreed for several key markets around nanoenzalutamide1). First term sheet also signed around nanoencorafenib2). Negotiations... ► Artikel lesen | |
| 15.04.25 | Nanoform Finland Oyj: Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc | 1.006 | GlobeNewswire (Europe) | Company release
Nanoform Finland Plc
April 15, 2025
14.10 Finnish time / 13.10 Swedish time
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Nanoform Finland... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,950 | +0,44 % | EQS-News: Formycon AG: Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Studienergebnisse/Studie
Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt
25.02.2026... ► Artikel lesen | |
| RIBER | 5,790 | -2,03 % | RIBER: 2025 performance driven by production systems and the rollout of ROSIE | 2025 performance driven by production systems and the rollout of ROSIE Revenues of €40.3 million in line with guidanceOrder book at December 31, 2025: €26.9 million (+24%) Bezons (France), February... ► Artikel lesen | |
| GOMSPACE | 1,688 | -1,86 % | GomSpace Group AB: GomSpace Reports an all-time high Q4 and a full year of significant growth | GomSpace delivers all-time high revenue, threefold growth in EBITDA, and secures major contracts for 2026, supported by a strong year-end balance sheet and cash position, as well as a 12% backlog increase... ► Artikel lesen | |
| ONTO INNOVATION | 185,00 | +1,09 % | ONTO INNOVATION INC. - 10-K, Annual Report | ||
| SOLESENCE | 1,260 | -4,91 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| CANATU | 9,400 | +1,95 % | Canatu Oyj: Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full windshield heaters | Canatu Plc Press release 2 January 2026 at 09:00 am EET
Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full... ► Artikel lesen | |
| VEECO INSTRUMENTS | 25,800 | -0,77 % | Veeco Instruments Inc.: Veeco Announces Upcoming Investor Events | ||
| NANOVEU | 0,048 | +24,10 % | NANOVEU LIMITED: Appendix 4G & Corporate Governance Statement | ||
| GAUZY | 0,500 | -1,96 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Board Composition Requirements | TEL AVIV, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that it has received... ► Artikel lesen | |
| NVE | 60,00 | +2,56 % | Dividendenbekanntmachungen (02.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY INC US00508Y1029 0,2 USD 0,1687 EUR ALLY FINANCIAL INC US02005N1000 0,3 USD 0,2531 EUR AMERISERV FINANCIAL INC US03074A1025 0... ► Artikel lesen | |
| OBDUCAT | 0,006 | +77,78 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| KOPIN | 1,843 | 0,00 % | Kopin Corporation: Michael Murray, Kopin's CEO to Present at THEON International's Capital Markets Day (CMD) on November 6, 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen | |
| ACACIA RESEARCH | 3,460 | +2,98 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| ADVANCE ZINCTEK | 0,515 | 0,00 % | ADVANCE ZINCTEK LIMITED: Half Yearly Report and Accounts | ||
| LAMPETIA | 0,094 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen |
Das Unternehmen NANOFORM FINLAND OYJ kann der Branche Nanotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,09 % bei einem Aktienkurs von 0,739 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.